Database : MEDLINE
Search on : mycosis and fungoides [Words]
References found : 5896 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 590 go to page                         

  1 / 5896 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29098990
[Au] Autor:Sharma P; Goyal S; Yadav AK; Singh J; Mandal AK
[Ad] Address:Department of Pathology, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India.
[Ti] Title:Hodgkin's lymphoma arising in a case of mycosis fungoides: An unusual association.
[So] Source:Indian J Dermatol Venereol Leprol;, 2017 Nov 03.
[Is] ISSN:0973-3922
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Mycosis fungoides is a cutaneous T-cell lymphoma with a high risk for developing secondary malignancies, especially B-cell lymphoproliferative disorders. About 40 cases of Hodgkin's lymphoma associated with mycosis fungoides have been reported in literature till date. We report a case of a 35-year-old gentleman who presented with intensely itchy reddish lesions all over the body. Multiple skin biopsies taken from the lesions on scalp and back confirmed the clinical diagnosis of mycosis fungoides. While on treatment, he presented with multiple bilateral cervical, axillary and inguinal lymphadenopathy 9 years after the primary diagnosis of mycosis fungoides. Excision biopsy of a cervical lymph node revealed partial effacement of architecture by a tumor comprising polymorphous background. Histopathology and immunohistochemistry revealed a diagnosis of Hodgkin's lymphoma - nodular sclerosis subtype. The patient was started on chemotherapy for stage IV Hodgkin's lymphoma. Our case emphasizes the importance of keeping secondary Hodgkin's lymphoma in mind while dealing with a patient of mycosis fungoides. Our case immunohistochemically supports the distinct etiopathogenesis of Epstein-Barr virus-negative Hodgkin's lymphoma vis-à-vis cutaneous mycosis fungoides.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1711
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher
[do] DOI:10.4103/ijdvl.IJDVL_744_16

  2 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28342276
[Au] Autor:Brown RA; Fernandez-Pol S; Kim J
[Ad] Address:Department of Pathology, Stanford University School of Medicine, Stanford, California.
[Ti] Title:Primary cutaneous anaplastic large cell lymphoma.
[So] Source:J Cutan Pathol;44(6):570-577, 2017 Jun.
[Is] ISSN:1600-0560
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease. CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1703
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:In-Process
[do] DOI:10.1111/cup.12937

  3 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28218382
[Au] Autor:Pedretti S; Urpis M; Leali C; Borghetti P; Baushi L; Sala R; Tucci A; Greco D; Pasinetti N; Triggiani L; Rossi G; Calzavara-Pinton P; Magrini SM; Buglione M
[Ad] Address:Radiation Oncology Department, Azienda Ospedaliera Spedali Civili di Brescia and Brescia University, Brescia - Italy.
[Ti] Title:Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.
[So] Source:Tumori;:0, 2017 Feb 14.
[Is] ISSN:2038-2529
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:PURPOSE: To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy. METHODS: From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Clinical and therapeutic characteristics (age, sex, histology, primary treatment and radiotherapy modality) were related to response to treatment, survival and toxicity. RESULTS: CBCLs were divided into 4 subgroups: marginal-zone lymphoma (n = 20), follicle center lymphoma (n = 32), diffuse large-cell lymphoma (DLBCL; n = 22) and DLBCL-leg type (n = 12). No significant correlation was found between doses and systemic treatments, extent of biopsy and number of lesions. DLBCL-leg type patients were older (p = 0.05), had disseminated disease (p = 0.034), and more frequently had local (p = 0.01) or systemic recurrence (p = 0.05). CTCLs were divided into 4 subgroups: α/ß CTCL (n = 3), nasal type CTCL (n = 0), γ/δ CTCL (n = 10) and mycosis fungoides (n = 10). Longer disease-free survival was observed in patients obtaining complete remission (p<0.001). CONCLUSIONS: Radiotherapy is feasible, safe and effective for localized PCLs. The choice of dose is related to histological subgroups and the related prognoses. Survival results are very good also in relapsing disease. In advanced cutaneous lymphoma radiotherapy alone has mainly a role in symptom palliation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1702
[Cu] Class update date: 171103
[Lr] Last revision date:171103
[St] Status:Publisher

  4 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28916993
[Au] Autor:Murota H; Lingli Y; Katayama I
[Ad] Address:Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 5650871, Japan. h-murota@derma.med.osaka-u.ac.jp.
[Ti] Title:Periostin in the pathogenesis of skin diseases.
[So] Source:Cell Mol Life Sci;74(23):4321-4328, 2017 Dec.
[Is] ISSN:1420-9071
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:Skin is an organ that is susceptible to damage by external injury, chronic inflammation, and autoimmunity. Tissue damage causes alterations in both the configuration and type of cells in lesional skin. This phenomenon, called tissue remodeling, is a universal biological response elicited by programmed cell death, inflammation, immune disorders, and tumorigenic, tumor proliferative, and cytoreductive activity. In this process, changes in the components of the extracellular matrix are required to provide an environment that facilitates tissue remodeling. Among these extracellular matrix components, periostin, a glycoprotein that is predominantly secreted from dermal fibroblasts, has attracted attention. Periostin localizes in the papillary dermis of normal skin, and is aberrantly expressed in the dermis of lesional skin in atopic dermatitis, scar, systemic/limited scleroderma, melanoma, cutaneous T cell lymphoma, and skin damage caused by allergic/autoimmune responses. Periostin induces processes that result in the development of dermal fibrosis, and activate or protract the immune response. The aim of this review was to summarize recent knowledge of the role of periostin in the pathogenesis of dermatoses, and to explore whether periostin is a potential therapeutic target for skin diseases.
[Mh] MeSH terms primary: Cell Adhesion Molecules/genetics
Dermatitis, Atopic/genetics
Fibroblasts/pathology
Melanoma/genetics
Scleroderma, Systemic/genetics
Skin Neoplasms/genetics
[Mh] MeSH terms secundary: Animals
Cell Adhesion Molecules/immunology
Cell Differentiation
Collagen Type I/genetics
Collagen Type I/immunology
Cytokines/genetics
Cytokines/immunology
Dermatitis, Atopic/immunology
Dermatitis, Atopic/pathology
Extracellular Matrix/immunology
Extracellular Matrix/pathology
Fibroblasts/immunology
Fibrosis
Gene Expression Regulation
Humans
Inflammation
Melanoma/immunology
Melanoma/pathology
Scleroderma, Systemic/immunology
Scleroderma, Systemic/pathology
Signal Transduction
Skin/immunology
Skin/pathology
Skin Neoplasms/immunology
Skin Neoplasms/pathology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Cell Adhesion Molecules); 0 (Collagen Type I); 0 (Cytokines); 0 (POSTN protein, human)
[Em] Entry month:1711
[Cu] Class update date: 171101
[Lr] Last revision date:171101
[Js] Journal subset:IM
[Da] Date of entry for processing:170916
[St] Status:MEDLINE
[do] DOI:10.1007/s00018-017-2647-1

  5 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29086994
[Au] Autor:van Santen S; Jansen PM; Vermeer MH; Willemze R
[Ad] Address:Departments of Dermatology, Leiden University Medical Center, The Netherlands.
[Ti] Title:Folliculotropic mycosis fungoides presenting with a solitary lesion: clinicopathological features and long-term follow-up data in a series of nine cases.
[So] Source:J Cutan Pathol;, 2017 Oct 31.
[Is] ISSN:1600-0560
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Folliculotropic mycosis fungoides (FMF) is a rare but distinct variant of mycosis fungoides (MF), histologically characterized by the presence of folliculotropic infiltrates, often with sparing of the epidermis, and clinically by the preferential involvement of the head and neck region. .
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171031
[Lr] Last revision date:171031
[St] Status:Publisher
[do] DOI:10.1111/cup.13077

  6 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28271282
[Au] Autor:Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
[Ad] Address:Division of Neuro-Oncology, Department of Neurology and Neurological Sciences, Stanford University, 875 Blake Wilbur Drive, CC 2221, Stanford, CA, 94305-5826, USA.
[Ti] Title:Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
[So] Source:J Neurooncol;132(3):439-446, 2017 May.
[Is] ISSN:1573-7373
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Chemotherapy-induced peripheral neuropathy (CIPN) is common, frequently limits chemotherapy dosing, and negatively impacts quality of life. The National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0, and the Total Neuropathy Score clinical version (TNSc) are both validated scores to quantify peripheral neuropathy (PN), with the TNSc being more sensitive to clinical changes. Mycosis fungoides and Sézary syndrome (MF/SS) are characterized by a chronic course, where current therapies are generally non-curative and treatment toxicities have the potential for significant lasting effects. Brentuximab vedotin (BV) is an antibody-drug-conjugate composed of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent, monomethyl auristatin E, with a known associated CIPN. In our phase II clinical trial of BV in MF/SS, 25 (69%) of 36 patients developed PN, with 18 (50%) developing Clinically Significant PN, CTCAE v4.0 grade 2 or higher. The median time to grade 2 PN was 15 weeks (range 0.4-48) after the initial dose. By Kaplan-Meier calculation, the median time to improvement from Clinically Significant PN was 30 weeks from the last BV dose. Seventy-four percent had improvement by 24 months. We found that TNSc scores significantly correlated with CTCAE grade, with Spearman correlation coefficient 0.68 (p < 0.001). By logistic regression, for each 100 mg increase in BV total dose, the likelihood of developing Clinically Significant PN increased by 23% (95% CI 4-46%). Improved monitoring of CIPN associated with BV is of paramount importance in the MF/SS population.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1703
[Cu] Class update date: 171030
[Lr] Last revision date:171030
[St] Status:In-Process
[do] DOI:10.1007/s11060-017-2389-9

  7 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28240409
[Au] Autor:Baykal C; Atci T; Ozturk Sari S; Polat Ekinci A; Buyukbabani N
[Ad] Address:Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
[Ti] Title:Underrecognized clinical features of folliculotropic mycosis fungoides: a large clinical series.
[So] Source:J Dtsch Dermatol Ges;15(3):289-299, 2017 Mar.
[Is] ISSN:1610-0387
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:BACKGROUND AND OBJECTIVE: A rare variant of mycosis fungoides (MF), folliculotropic MF (FMF) is characterized by a broad clinical spectrum that primarily includes follicle-based lesions but also many atypical clinical manifestations. The objective of the present study was to conduct a clinical analysis of patients with FMF, with a particular focus on highlighting underrecognized dermatological features. PATIENTS AND METHODS: Overall, 27 FMF patients enrolled in our department';s MF registry, which includes 572 patients, were retrospectively reevaluated with regard to demographics, clinical features, treatment modalities, follow-up, and outcomes. RESULTS: Besides the well-known clinical features of FMF, we found lichen spinulosus-like lesions in association with hypopigmentation (n = 3) and alopecia (n = 2), infiltrated/elevated erythematous facial plaques initially considered to be lupus tumidus (n = 2), pseudotumoral lesions clinically mimicking tumor-stage MF (n = 1), persistent excoriations (n = 1) and erythematous facial papules mimicking rosacea (n = 1), as well as white dome-shaped asymptomatic papules/nodules filled with mucin (on histology) (n = 2) that overlay other disease-related lesions. Various therapeutic methods were used with variable results. Eight (29.6 %) patients had late-stage disease. CONCLUSIONS: Awareness of underrecognized clinical manifestations may be key to reducing delayed diagnosis of this aggressive MF variant.
[Mh] MeSH terms primary: Clinical Competence/statistics & numerical data
Diagnostic Errors/statistics & numerical data
Mycosis Fungoides/epidemiology
Mycosis Fungoides/pathology
Skin Neoplasms/epidemiology
Skin Neoplasms/pathology
[Mh] MeSH terms secundary: Adolescent
Adult
Age Distribution
Aged
Child
Diagnostic Errors/prevention & control
False Negative Reactions
Female
Humans
Male
Middle Aged
Mycosis Fungoides/therapy
Prevalence
Reproducibility of Results
Risk Factors
Sensitivity and Specificity
Sex Distribution
Skin Neoplasms/therapy
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171030
[Lr] Last revision date:171030
[Js] Journal subset:IM
[Da] Date of entry for processing:170227
[St] Status:MEDLINE
[do] DOI:10.1111/ddg.12976

  8 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29080377
[Au] Autor:Weyand AC; Hristov A; Tejasvi T; Walkovich K
[Ad] Address:Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.
[Ti] Title:A diagnosis of mycosis fungoides in a pediatric patient with recurrent Langerhans cell histiocytosis.
[So] Source:Pediatr Blood Cancer;, 2017 Oct 28.
[Is] ISSN:1545-5017
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1710
[Cu] Class update date: 171028
[Lr] Last revision date:171028
[St] Status:Publisher
[do] DOI:10.1002/pbc.26835

  9 / 5896 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29068084
[Au] Autor:Hamada T; Nomura H; Iwatsuki K
[Ad] Address:Departments of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
[Ti] Title:Regional incidences of adult T-cell leukemia/lymphoma with cutaneous involvement in Japan.
[So] Source:J Dermatol;, 2017 Oct 25.
[Is] ISSN:1346-8138
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Between 2008 and 2015, 462 newly-diagnosed adult T-cell leukemia/lymphoma (ATLL) patients with cutaneous involvement were found from the nationwide registry for Japanese patients with cutaneous lymphoma, of which 391 were selected for the study. They ranged in age from 28 to 93 years (median, 69 years), and included 215 men and 176 women (male : female ratio = 1.2). The 391 patients comprised 193 (50%) with smoldering type, 52 (13%) with chronic type, 44 (11%) with lymphoma type and 102 (26%) with acute type. The total number of patients in Kyushu/Okinawa was 8.8-times higher than that in Kanto, which was set as the reference value, while the estimated prevalence of human T-lymphotropic virus 1 (HTLV-1) carriers in Kyushu/Okinawa has been reported to be only 2.5-times higher than that in Kanto. In this study, the annual incidence of ATLL per 100 000 residents in Kyushu/Okinawa was 32-times higher than that in Kanto. Our results indicated the higher incidence rate of ATLL in the endemic area than those in the non-endemic areas in Japan, compared with the regional differences of HTLV-1 prevalence determined by serological HTLV-1 screening for blood donors. In addition, this analysis revealed that regional differences of mycosis fungoides/Sézary syndrome incidence rates were very small compared with those of ATLL.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171025
[Lr] Last revision date:171025
[St] Status:Publisher
[do] DOI:10.1111/1346-8138.14100

  10 / 5896 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29068082
[Au] Autor:Fujimura T; Furudate S; Tanita K; Sato Y; Kambayashi Y; Hidaka T; Aiba S
[Ad] Address:Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
[Ti] Title:Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy.
[So] Source:J Dermatol;, 2017 Oct 25.
[Is] ISSN:1346-8138
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1710
[Cu] Class update date: 171025
[Lr] Last revision date:171025
[St] Status:Publisher
[do] DOI:10.1111/1346-8138.14111


page 1 of 590 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information